MA43825A - Schémas posologiques pour le traitement d'infections fongiques - Google Patents

Schémas posologiques pour le traitement d'infections fongiques

Info

Publication number
MA43825A
MA43825A MA043825A MA43825A MA43825A MA 43825 A MA43825 A MA 43825A MA 043825 A MA043825 A MA 043825A MA 43825 A MA43825 A MA 43825A MA 43825 A MA43825 A MA 43825A
Authority
MA
Morocco
Prior art keywords
treatment
fungal infections
dosage schedules
schedules
dosage
Prior art date
Application number
MA043825A
Other languages
English (en)
Inventor
Kenneth Bartizal
Paul Daruwala
Jeffrey Brian Locke
Voon Ong
Taylor Sandison
Dirk Thye
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of MA43825A publication Critical patent/MA43825A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043825A 2016-03-16 2017-03-15 Schémas posologiques pour le traitement d'infections fongiques MA43825A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662309211P 2016-03-16 2016-03-16
US201662350591P 2016-06-15 2016-06-15
US201662415928P 2016-11-01 2016-11-01
US201662418727P 2016-11-07 2016-11-07
US201662419076P 2016-11-08 2016-11-08
US201662436716P 2016-12-20 2016-12-20

Publications (1)

Publication Number Publication Date
MA43825A true MA43825A (fr) 2021-04-07

Family

ID=59850952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043825A MA43825A (fr) 2016-03-16 2017-03-15 Schémas posologiques pour le traitement d'infections fongiques

Country Status (8)

Country Link
US (2) US11712459B2 (fr)
EP (2) EP4268896A3 (fr)
JP (3) JP7224916B2 (fr)
CN (1) CN109154603A (fr)
CA (1) CA3017485A1 (fr)
ES (1) ES2955711T3 (fr)
MA (1) MA43825A (fr)
WO (1) WO2017161016A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2680873B1 (fr) 2011-03-03 2017-08-09 Cidara Therapeutics, Inc. Agents antifongiques et leurs utilisations
HRP20231151T1 (hr) 2012-03-19 2024-01-05 Cidara Therapeutics, Inc. Režimi za doziranje spojeva iz klase ehinokandina
WO2017120471A1 (fr) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Procédés de prévention et de traitement d'infections à pneumocystis
CN109154603A (zh) 2016-03-16 2019-01-04 奇达拉治疗公司 用于治疗真菌感染的给药方案
CA3069423C (fr) 2017-07-12 2025-04-15 Napp Pharmaceutical Group Limited Formulations pour le traitement des infections fongiques
US11524980B2 (en) 2018-06-15 2022-12-13 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent
WO2020086931A1 (fr) 2018-10-25 2020-04-30 Cidara Therapeutics, Inc. Polymorphe d'un agent antifongique de type échinocandine
IL288165B2 (en) * 2019-05-16 2026-05-01 Scynexis Inc Antifungal agents for decolonization of Candida auris

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
CA2161149A1 (fr) 1993-05-04 1994-11-10 James M. Balkovec Ether-oxydes de cyclohexapeptidyle et d'aminoalkyle
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
ATE206054T1 (de) 1995-01-26 2001-10-15 Merck & Co Inc Neue fungizide cyclohexapeptide
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
PE63998A1 (es) 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
AU766091B2 (en) 1998-12-09 2003-10-09 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2002538097A (ja) 1999-03-03 2002-11-12 イーライ リリー アンド カンパニー 薬学的経口ｅｃｂ処方物および組成物の作製方法
EP1582204B1 (fr) 1999-03-03 2013-09-25 Eli Lilly & Company Formulations pharmaceutiques d'échinocandine contenant des tensioactifs formant des micelles
US6309622B1 (en) 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
EP1172105A4 (fr) 1999-04-16 2002-09-04 Fujisawa Pharmaceutical Co Compositions antifongiques
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
CA2502148A1 (fr) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Procedes et compositions pour augmenter l'efficacite de substances actives d'un point de vue biologique
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
DE602004010915T2 (de) 2003-07-22 2008-12-11 Theravance, Inc., South San Francisco Verwendung eines antimykotischen echinocandin-mittels in kombination mit einem antibakteriellen glycopeptid-mittel
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
AU2006272568B2 (en) 2005-07-26 2012-06-28 Merck Sharp & Dohme Corp. Assays for resistance to echinocandin-class drugs
WO2007113386A1 (fr) 2006-03-31 2007-10-11 Karyon-Ctt Ltd Conjugués peptidiques
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
KR101725196B1 (ko) 2009-02-25 2017-04-10 스티펠 리서치 오스트레일리아 피티와이 리미티드 국소 폼 조성물
ES2461596T3 (es) 2009-05-07 2014-05-20 Dsm Sinochem Pharmaceuticals Netherlands B.V. Método para la preparación de ciclopéptidos
SI2470168T1 (en) 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
EP2470190A4 (fr) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc Dérivés d échinocandine
WO2011089214A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de carbamates liés à des supports
EP2680873B1 (fr) 2011-03-03 2017-08-09 Cidara Therapeutics, Inc. Agents antifongiques et leurs utilisations
EP2739652B1 (fr) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Inhibiteurs cahgt1p à utiliser dans le traitement de la candidose
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
HRP20231151T1 (hr) 2012-03-19 2024-01-05 Cidara Therapeutics, Inc. Režimi za doziranje spojeva iz klase ehinokandina
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (fr) 2013-01-18 2014-07-24 University Of Utah Research Foundation Pompe osmotique à libération modifiée pour administration intravaginale de médicament réagissant au ph
WO2014124504A1 (fr) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions et méthodes de traitement de biofilms
WO2014145109A1 (fr) 2013-03-15 2014-09-18 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Conjugués de médicament-séquence de liaison du sucre
CA2910752C (fr) * 2013-05-01 2021-11-23 Neoculi Pty Ltd Utilisation de la robenidine pour traiter une infection bacterienne
WO2015035102A2 (fr) * 2013-09-04 2015-03-12 Cidara Therapeutics, Inc. Compositions et méthodes pour le traitement d'infections fongiques
WO2017049102A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Méthodes de traitement d'infections fongiques
WO2017049105A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations pour le traitement d'infections fongiques
WO2017120471A1 (fr) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Procédés de prévention et de traitement d'infections à pneumocystis
CN109154603A (zh) 2016-03-16 2019-01-04 奇达拉治疗公司 用于治疗真菌感染的给药方案
WO2018085200A1 (fr) 2016-11-01 2018-05-11 Cidara Therapeutics, Inc. Méthodes à dose unique pour la prévention et le traitement d'infections fongiques
US20210002346A1 (en) 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
JP2020505427A (ja) 2017-01-31 2020-02-20 シダラ セラピューティクス インコーポレーテッド 真菌感染症を治療する方法
WO2018187574A1 (fr) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions et procédés de traitement d'infections fongiques
WO2018191692A1 (fr) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
CA3069423C (fr) 2017-07-12 2025-04-15 Napp Pharmaceutical Group Limited Formulations pour le traitement des infections fongiques
AU2018311375A1 (en) 2017-08-03 2020-03-12 Napp Pharmaceutical Group Limited Methods for preventing and treating intra-abdominal candidiasis
US11524980B2 (en) 2018-06-15 2022-12-13 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent

Also Published As

Publication number Publication date
JP7322259B2 (ja) 2023-08-07
US11712459B2 (en) 2023-08-01
US20190216885A1 (en) 2019-07-18
WO2017161016A1 (fr) 2017-09-21
US20240108684A1 (en) 2024-04-04
JP7224916B2 (ja) 2023-02-20
EP3430400A4 (fr) 2019-10-30
EP3430400B1 (fr) 2023-06-21
EP4268896A2 (fr) 2023-11-01
JP2022169599A (ja) 2022-11-09
JP2019511496A (ja) 2019-04-25
ES2955711T3 (es) 2023-12-05
EP4268896A3 (fr) 2024-01-03
JP2023139211A (ja) 2023-10-03
CA3017485A1 (fr) 2017-09-21
EP3430400A1 (fr) 2019-01-23
CN109154603A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA45192A (fr) Traitement d'association
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3430400A4 (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3651801A4 (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3495118A4 (fr) Composition d'agent de traitement pour précurseur d'objet tridimensionnel